Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 182Endometrial Neoplasms 114Uterine Cervical Neoplasms 101Breast Neoplasms 60Colorectal Neoplasms 51Fallopian Tube Neoplasms 45Carcinoma, Non-Small-Cell Lung 43Neoplasms 37Pancreatic Neoplasms 34Prostatic Neoplasms 28Stomach Neoplasms 27Neoplasm Metastasis 27Melanoma 25Squamous Cell Carcinoma of Head and Neck 23Esophageal Neoplasms 23Lung Neoplasms 22Triple Negative Breast Neoplasms 20Carcinoma, Ovarian Epithelial 20Carcinoma, Renal Cell 19Urinary Bladder Neoplasms 18Head and Neck Neoplasms 18Colonic Neoplasms 17Sarcoma 16Carcinoma, Transitional Cell 16Carcinoma, Hepatocellular 15Uterine Neoplasms 14Small Cell Lung Carcinoma 14Cholangiocarcinoma 14Vulvar Neoplasms 13Rectal Neoplasms 13

Interventions

Specimen Handling 1Biopsy 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Serous Adenocarcinoma × Gynecologic × 30 days × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡